Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Releases FY 2026 Earnings Guidance

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 1.200-1.346 for the period, compared to the consensus earnings per share estimate of 1.200. The company issued revenue guidance of $52.1 billion-$54.5 billion, compared to the consensus revenue estimate of $53.2 billion.

Bayer Aktiengesellschaft Price Performance

Shares of BAYRY stock opened at $11.06 on Thursday. The stock has a 50 day moving average of $11.27 and a two-hundred day moving average of $10.96. The company has a current ratio of 1.01, a quick ratio of 0.63 and a debt-to-equity ratio of 1.22. Bayer Aktiengesellschaft has a 12 month low of $6.20 and a 12 month high of $14.85. The company has a market capitalization of $43.47 billion, a P/E ratio of -17.28 and a beta of 0.62.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. The company had revenue of $15.73 billion during the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft had a positive return on equity of 17.74% and a negative net margin of 4.75%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, equities analysts expect that Bayer Aktiengesellschaft will post 1.22 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BAYRY. UBS Group raised shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a report on Monday, March 16th. DZ Bank upgraded Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 9th. Finally, Zacks Research upgraded Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Bayer Aktiengesellschaft currently has an average rating of “Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.